Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Excretion Clear all

Conditions: Healthy Volunteer
Interventions: [14C]-EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer
Interventions: [14C]-BIIB091; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Teriflunomide Elimination, Healthy Volunteers
Interventions: teriflunomide, Colestipol; Drug
Lead sponsor: Derrick Scott Robertson; Other
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy Adult Male
Interventions: [14C]-VVZ-149; Drug
Lead sponsor: Vivozon, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Food Sensitivity
Interventions: Elimination Diet; Behavioral
Lead sponsor: Vibrant America Clinical Lab; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Gilbert, Arizona • Scottsdale, Arizona • San Carlos, California + 5 more

Conditions: Metabolites, Gut Microbiota
Interventions: curcumin; Dietary Supplement
Lead sponsor: University of Massachusetts, Amherst; Other
Eligibility: 18 Years to 30 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Amherst, Massachusetts

Conditions: Healthy
Interventions: [phenyl-14C]ARV-471, [oxoisoindolin-14C]ARV-471; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: [14C]PF00299804; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy Volunteers
Interventions: [14C]-DNL343; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Anal Incontinence, Fecal Incontinence
Interventions: Eccentric Training, Concentric Training, Isometric Training, Biofeedback; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 22 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Hepatitis B
Interventions: Vebicorvir (VBR); Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Eosinophilic Esophagitis, EoE
Interventions: Algorithm to diagnose food allergens, Sham diet; Device · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Radiolabeled Prucalopride Succinate; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Tauopathies
Interventions: 18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments; Drug · Diagnostic Test · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: San Francisco, California • Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: 14C-labeled ASP0367; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]-CTP-543; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: LY4065967, [14C]-LY4065967 Oral, [14C]-LY4065967 IV; Drug · Radiation
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Guselkumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Encopresis
Interventions: Internet Intervention + Stepped Care, Internet Intervention, Patient Education Website; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 5 Years to 12 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Fecal Incontinence
Interventions: The Leva Pelvic Health System; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hepatitis C, Pregnancy Complications, Vertical Disease Transmission
Interventions: SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg; Drug
Lead sponsor: The Christ Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: [14C]-YH4808 200 mg; Drug
Lead sponsor: Yuhan Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]-LX4211; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Atrial Fibrillation, Arrhythmias, Cardiac
Interventions: Standard Atrial fibrillation ablation, Coronary sinus to left atrium connection elimination; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants

Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

Effect of Personalized Elimination Diet on Food Sensitivity Related Symptoms

Interindividual Variation in Excretion of Curcumin

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

Physical Therapy for Anal Incontinence

A Study to Evaluate the Mass Balance Absorption and AME of VBR

The Immune Directed Individualized Elimination Therapy (iDIET) Study

Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

A Study of [14C]-LY4065967 in Healthy Participants

A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants

Internet Intervention for Childhood Encopresis

Use of the LEVA® Pelvic Health System for Fecal Incontinence

Transmission of Chronic Hepatitis C in Pregnancy

AME Study of [14C]-YH4808 in Healthy Male Subjects

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial